JP2016516403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516403A5 JP2016516403A5 JP2015562411A JP2015562411A JP2016516403A5 JP 2016516403 A5 JP2016516403 A5 JP 2016516403A5 JP 2015562411 A JP2015562411 A JP 2015562411A JP 2015562411 A JP2015562411 A JP 2015562411A JP 2016516403 A5 JP2016516403 A5 JP 2016516403A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- interest
- amplification
- expression level
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 139
- 238000000034 method Methods 0.000 claims description 104
- 230000014509 gene expression Effects 0.000 claims description 92
- 239000000523 sample Substances 0.000 claims description 60
- 206010028980 Neoplasm Diseases 0.000 claims description 54
- 206010027476 Metastases Diseases 0.000 claims description 51
- 230000009401 metastasis Effects 0.000 claims description 51
- 201000011510 cancer Diseases 0.000 claims description 45
- 230000003321 amplification Effects 0.000 claims description 43
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 43
- 239000003112 inhibitor Substances 0.000 claims description 36
- 210000000988 bone and bone Anatomy 0.000 claims description 34
- 102000014128 RANK Ligand Human genes 0.000 claims description 31
- 108010025832 RANK Ligand Proteins 0.000 claims description 31
- 102100039189 Transcription factor Maf Human genes 0.000 claims description 26
- 238000000338 in vitro Methods 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 19
- 102100026199 C-type lectin domain family 3 member A Human genes 0.000 claims description 15
- 101000912587 Homo sapiens C-type lectin domain family 3 member A Proteins 0.000 claims description 15
- 101000750321 Homo sapiens Synaptic vesicle membrane protein VAT-1 homolog-like Proteins 0.000 claims description 15
- 102100021165 Synaptic vesicle membrane protein VAT-1 homolog-like Human genes 0.000 claims description 15
- 108010036639 WW Domain-Containing Oxidoreductase Proteins 0.000 claims description 15
- 102100027534 WW domain-containing oxidoreductase Human genes 0.000 claims description 15
- 229940122361 Bisphosphonate Drugs 0.000 claims description 12
- 150000004663 bisphosphonates Chemical class 0.000 claims description 12
- 239000013068 control sample Substances 0.000 claims description 12
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 11
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 10
- 230000015556 catabolic process Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 238000006731 degradation reaction Methods 0.000 claims description 9
- 229940125436 dual inhibitor Drugs 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 102000055006 Calcitonin Human genes 0.000 claims description 7
- 108060001064 Calcitonin Proteins 0.000 claims description 7
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 7
- 229960004015 calcitonin Drugs 0.000 claims description 7
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 7
- 230000002759 chromosomal effect Effects 0.000 claims description 7
- 239000002834 estrogen receptor modulator Substances 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 claims description 7
- 229960005562 radium-223 Drugs 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 108020004635 Complementary DNA Proteins 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
- 238000010804 cDNA synthesis Methods 0.000 claims description 6
- 239000002299 complementary DNA Substances 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 201000002510 thyroid cancer Diseases 0.000 claims description 6
- 229940097000 DKK-1 inhibitor Drugs 0.000 claims description 5
- 206010027452 Metastases to bone Diseases 0.000 claims description 5
- 102000008108 Osteoprotegerin Human genes 0.000 claims description 5
- 108010035042 Osteoprotegerin Proteins 0.000 claims description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- QHLITPHIARVDJI-UHFFFAOYSA-N [1-[4-(2-naphthalenyl)-2-pyrimidinyl]-4-piperidinyl]methanamine Chemical compound C1CC(CN)CCN1C1=NC=CC(C=2C=C3C=CC=CC3=CC=2)=N1 QHLITPHIARVDJI-UHFFFAOYSA-N 0.000 claims description 5
- 229940111134 coxibs Drugs 0.000 claims description 5
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 5
- 229960001251 denosumab Drugs 0.000 claims description 5
- 230000009977 dual effect Effects 0.000 claims description 5
- 229940043355 kinase inhibitor Drugs 0.000 claims description 5
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 5
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 5
- 230000003472 neutralizing effect Effects 0.000 claims description 5
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 claims description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 238000011002 quantification Methods 0.000 claims description 5
- 229940079488 strontium ranelate Drugs 0.000 claims description 5
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 claims description 5
- 238000011269 treatment regimen Methods 0.000 claims description 5
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical group OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 5
- 229960004276 zoledronic acid Drugs 0.000 claims description 5
- 229940122156 Cathepsin K inhibitor Drugs 0.000 claims description 4
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims description 4
- 208000003076 Osteolysis Diseases 0.000 claims description 4
- 229960001292 cabozantinib Drugs 0.000 claims description 4
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical group C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims description 4
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims description 4
- 238000003752 polymerase chain reaction Methods 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 230000005945 translocation Effects 0.000 claims description 4
- 102000004171 Cathepsin K Human genes 0.000 claims description 3
- 108090000625 Cathepsin K Proteins 0.000 claims description 3
- 101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 claims description 3
- 102100036899 Parathyroid hormone-related protein Human genes 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 238000002965 ELISA Methods 0.000 claims description 2
- 238000003491 array Methods 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims description 2
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 238000007901 in situ hybridization Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 238000003498 protein array Methods 0.000 claims description 2
- 238000003753 real-time PCR Methods 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 102100036893 Parathyroid hormone Human genes 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 238000001794 hormone therapy Methods 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 238000011338 personalized therapy Methods 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 229910052712 strontium Inorganic materials 0.000 claims 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 101000962461 Homo sapiens Transcription factor Maf Proteins 0.000 description 6
- 101000613608 Rattus norvegicus Monocyte to macrophage differentiation factor Proteins 0.000 description 6
- 102000001332 SRC Human genes 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000010 osteolytic effect Effects 0.000 description 3
- 108010087686 src-Family Kinases Proteins 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 description 2
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 108020005075 5S Ribosomal RNA Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801718P | 2013-03-15 | 2013-03-15 | |
| US61/801,718 | 2013-03-15 | ||
| PCT/IB2014/001253 WO2014140933A2 (en) | 2013-03-15 | 2014-03-14 | Method for the prognosis and treatment of cancer metastasis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516403A JP2016516403A (ja) | 2016-06-09 |
| JP2016516403A5 true JP2016516403A5 (cg-RX-API-DMAC7.html) | 2017-11-16 |
| JP6577873B2 JP6577873B2 (ja) | 2019-09-18 |
Family
ID=51265712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562411A Active JP6577873B2 (ja) | 2013-03-15 | 2014-03-14 | がんの転移の予後診断および処置のための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20160032400A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2971113B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6577873B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20150122731A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105324491B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014229505B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015023783A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2906394A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2015011362A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014140933A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8338109B2 (en) | 2006-11-02 | 2012-12-25 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| US20110136683A1 (en) | 2008-05-28 | 2011-06-09 | Genomedx Biosciences, Inc. | Systems and Methods for Expression-Based Discrimination of Distinct Clinical Disease States in Prostate Cancer |
| US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US9074258B2 (en) | 2009-03-04 | 2015-07-07 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
| EP3360978A3 (en) | 2009-05-07 | 2018-09-26 | Veracyte, Inc. | Methods for diagnosis of thyroid conditions |
| US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
| US10047398B2 (en) | 2010-10-06 | 2018-08-14 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of breast cancer metastasis |
| US20130267443A1 (en) | 2010-11-19 | 2013-10-10 | The Regents Of The University Of Michigan | ncRNA AND USES THEREOF |
| EP2791359B1 (en) | 2011-12-13 | 2020-01-15 | Decipher Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| EP3435084B1 (en) | 2012-08-16 | 2023-02-22 | Decipher Biosciences, Inc. | Prostate cancer prognostics using biomarkers |
| BR112015008255B1 (pt) | 2012-10-12 | 2023-02-28 | Inbiomotion S.L | Métodos in vitro para diagnóstico ou prognóstico de metástase óssea em um indivíduo com câncer de próstata e método para classificar um indivíduo que sofre de câncer de próstata em uma coorte |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| WO2014186036A1 (en) | 2013-03-14 | 2014-11-20 | Allegro Diagnostics Corp. | Methods for evaluating copd status |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| BR112015023510A2 (pt) | 2013-03-15 | 2017-10-10 | Fundacio Inst De Recerca Biomedica Irb Barcelona | método para o diagnóstico, prognóstico e tratamento de câncer metastático |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| JP7356788B2 (ja) | 2014-11-05 | 2023-10-05 | ベラサイト インコーポレイテッド | 機械学習および高次元転写データを使用して経気管支生検における特発性肺線維症を診断するシステムおよび方法 |
| CA2967224C (en) | 2014-12-11 | 2023-08-22 | Inbiomotion S.L. | Binding members for human c-maf |
| CN109069634A (zh) * | 2016-02-18 | 2018-12-21 | 国立大学法人京都大学 | 能够抑制外泌体中的遗传功能的复合物以及癌症增殖和/或转移抑制剂 |
| JP2019513756A (ja) * | 2016-04-08 | 2019-05-30 | ザ クリーブランド クリニック ファウンデーションＴｈｅ Ｃｌｅｖｅｌａｎｄ ＣｌｉｎｉｃＦｏｕｎｄａｔｉｏｎ | 骨疾患を治療するための薬物送達用ナノ粒子 |
| WO2017198609A1 (en) * | 2016-05-19 | 2017-11-23 | Probiocon Gmbh | Anti-cancer combination treatment |
| DK3901283T3 (da) * | 2016-05-25 | 2025-09-15 | Inbiomotion Sl | Terapeutisk behandling af brystkræft baseret på c-maf-status |
| US20190234937A1 (en) * | 2016-07-12 | 2019-08-01 | The University Of North Carolina At Chapel Hill | Biomatrix scaffolds for use in diagnosing and modeling cancer |
| CN110506127B (zh) | 2016-08-24 | 2024-01-12 | 维拉科特Sd公司 | 基因组标签预测前列腺癌患者对术后放射疗法应答性的用途 |
| CA3050984A1 (en) | 2017-01-20 | 2018-07-26 | Decipher Biosciences, Inc. | Molecular subtyping, prognosis, and treatment of bladder cancer |
| EP3593140A4 (en) | 2017-03-09 | 2021-01-06 | Decipher Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
| EP3622087A4 (en) | 2017-05-12 | 2021-06-16 | Decipher Biosciences, Inc. | GENETIC SIGNATURES FOR PREDICTING PROSTATE CANCER METASTASIS AND IDENTIFYING TUMOR VIRULENCE |
| US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
| EP4428157A3 (en) | 2017-08-04 | 2024-12-11 | Veracyte SD, Inc. | Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy |
| MX2020005182A (es) | 2017-11-22 | 2020-08-17 | Inbiomotion Sl | Tratamiento terapeutico del cancer de mama basado en el estado del c-maf. |
| CN108084254A (zh) * | 2017-11-30 | 2018-05-29 | 天津市湖滨盘古基因科学发展有限公司 | 一种人的抗癌基因WWOXδ6-8突变蛋白及其应用 |
| WO2021185959A1 (en) * | 2020-03-19 | 2021-09-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Estrogen-related receptor alpha agonists for the treatment and the prognosis of bone metastases |
| CN115198013A (zh) * | 2021-04-14 | 2022-10-18 | 迪瑞药业(成都)有限公司 | 用以鉴别出适用精氨酸剥夺疗法的患者的方法与试剂盒 |
| EP4662329A1 (en) * | 2023-02-08 | 2025-12-17 | Iogenetics, LLC. | Cleaved neoepitopes |
| CN115919464B (zh) * | 2023-03-02 | 2023-06-23 | 四川爱麓智能科技有限公司 | 肿瘤定位方法、系统、装置及肿瘤发展预测方法 |
| CN119614707A (zh) * | 2025-01-13 | 2025-03-14 | 中山大学 | ERα生物标志物在ER+乳腺癌骨转移诊断、治疗和预后中的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1986004920A1 (en) | 1985-02-13 | 1986-08-28 | Biotechnology Research Partners, Limited | Human metallothionein-ii promoter in mammalian expression system |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| CA2251466A1 (en) | 1996-04-05 | 1997-10-16 | The Salk Institute For Biological Studies | Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| US6017729A (en) | 1996-12-23 | 2000-01-25 | Immunex Corporation | Receptor activator of NF-κB |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| EP1178958B1 (en) | 1999-03-15 | 2004-02-18 | Axys Pharmaceuticals, Inc. | N-cyanomethyl amides as protease inhibitors |
| US6287813B1 (en) | 1999-04-23 | 2001-09-11 | Cistronics Cell Technology Gmbh | Antibiotic-based gene regulation system |
| EP1248612B1 (en) | 2000-01-06 | 2008-02-27 | Merck Frosst Canada Ltd. | Novel compounds and compositions as protease inhibitors |
| US6750015B2 (en) | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| NO345566B1 (no) | 2001-06-26 | 2021-04-19 | Amgen Inc | OPGL bindende antistoff, farmasøytisk sammensetning samt anvendelse derav |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| AU2003903540A0 (en) | 2003-07-09 | 2003-07-24 | Atdec Pty Ltd | Flat panel display wall mounting system |
| US20050060771A1 (en) | 2003-09-11 | 2005-03-17 | Farmer Andrew Alan | siRNA encoding constructs and methods for using the same |
| WO2005046731A1 (en) | 2003-10-17 | 2005-05-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| US20090048117A1 (en) | 2003-12-18 | 2009-02-19 | President And Fellows Of Harvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| TW200526224A (en) | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| WO2006012221A2 (en) | 2004-06-25 | 2006-02-02 | The Regents Of The University Of California | Target cell-specific short interfering rna and methods of use thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| EP1969000A2 (en) | 2005-12-06 | 2008-09-17 | Centre National de la Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| EP1984024A2 (en) * | 2006-01-05 | 2008-10-29 | Novartis AG | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| EP2152747B1 (en) | 2007-05-24 | 2018-01-03 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| WO2010000796A1 (en) * | 2008-07-02 | 2010-01-07 | Assistance Publique - Hôpitaux De Paris | A method for predicting clinical outcome of patients with non-small cell lung carcinoma |
| US10047398B2 (en) * | 2010-10-06 | 2018-08-14 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of breast cancer metastasis |
| WO2012064967A2 (en) * | 2010-11-10 | 2012-05-18 | Cedars-Sinai Medical Center | Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases |
| EP2650682A1 (en) * | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) * | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
-
2014
- 2014-03-14 EP EP14747411.8A patent/EP2971113B1/en active Active
- 2014-03-14 BR BR112015023783A patent/BR112015023783A2/pt not_active Application Discontinuation
- 2014-03-14 JP JP2015562411A patent/JP6577873B2/ja active Active
- 2014-03-14 CN CN201480015564.0A patent/CN105324491B/zh active Active
- 2014-03-14 US US14/776,412 patent/US20160032400A1/en not_active Abandoned
- 2014-03-14 AU AU2014229505A patent/AU2014229505B2/en active Active
- 2014-03-14 KR KR1020157026432A patent/KR20150122731A/ko not_active Ceased
- 2014-03-14 MX MX2015011362A patent/MX2015011362A/es unknown
- 2014-03-14 WO PCT/IB2014/001253 patent/WO2014140933A2/en not_active Ceased
- 2014-03-14 CA CA2906394A patent/CA2906394A1/en active Pending
-
2015
- 2015-09-02 MX MX2020001156A patent/MX2020001156A/es unknown
-
2021
- 2021-04-27 US US17/241,571 patent/US20210317534A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516403A5 (cg-RX-API-DMAC7.html) | ||
| Shames et al. | High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck | |
| JP2016539625A5 (cg-RX-API-DMAC7.html) | ||
| JP2016105731A5 (cg-RX-API-DMAC7.html) | ||
| JP2018078911A5 (cg-RX-API-DMAC7.html) | ||
| Lee et al. | Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma | |
| JP2015521050A5 (cg-RX-API-DMAC7.html) | ||
| Ocana et al. | Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis | |
| JP2022125079A (ja) | がん転移の予後診断および処置のための方法 | |
| WO2013182912A4 (en) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | |
| Tobin et al. | The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer | |
| JP6735277B2 (ja) | 乳癌療法剤に対する反応を予測するための方法および乳癌の処置の方法 | |
| JP2019523641A5 (cg-RX-API-DMAC7.html) | ||
| JP2013541339A5 (cg-RX-API-DMAC7.html) | ||
| KR20120047912A (ko) | 암 요법에서 항ｅｇｆｒ 항체의 효능을 결정하기 위한 바이오마커 및 방법 | |
| Berezowska et al. | Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas | |
| JP6603474B2 (ja) | 癌治療 | |
| CN105980576A (zh) | 用于源自乳腺癌的骨转移癌的预后和治疗的方法 | |
| Zhang et al. | Knockdown of AXL receptor tyrosine kinase in osteosarcoma cells leads to decreased proliferation and increased apoptosis | |
| Charafe-Jauffret et al. | Defining the molecular biology of inflammatory breast cancer | |
| CN105765081A (zh) | 一种用于预测对采用egfr抑制剂的治疗的响应性的方法 | |
| EP2935620A1 (en) | Prediction of the treatment response to an anti-egfr molecule in colorectal cancer patients | |
| Krause et al. | Clinical biomarkers of kinase activity: examples from EGFR inhibition trials | |
| Stickeler | Prognostic and predictive markers for treatment decisions in early breast cancer | |
| KR20240157611A (ko) | 전이성 유방암의 항암제 치료 반응성 및 예후 예측용 신규한 바이오마커 및 이의 용도 |